QianJin Pharmaceutical(SH:600479) Jin Rong Jie·2026-02-09 08:52Core Insights - The company reported a total operating revenue of 3.635 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 0.13% [1] - The net profit reached 288 million yuan, showing a significant year-on-year increase of 24.74% [1] - The growth in performance is attributed to stable revenue growth from core industrial enterprises and improved profitability [1] Revenue and Profit Analysis - Total operating revenue for 2025 was 3.635 billion yuan, with a slight increase of 0.13% compared to the previous year [1] - Net profit for the same period was 288 million yuan, marking a substantial increase of 24.74% year-on-year [1] Strategic Acquisitions - The company acquired a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [1] - These acquisitions were consolidated into the financial statements starting from October and November 2025, respectively [1]